The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
5 Jun 2022
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...
Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
5 Jun 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
5 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
5 Jun 2022
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...
Dr Julie Gralow- Chief Medical Officer, ASCO
5 Jun 2022
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for...
Dr Martin McCabe- University of Manchester, Manchester, England
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
5 Jun 2022
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
5 Jun 2022